Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

NCT02630251 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class

Stopped In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.

Conditions

Interventions

Sponsor

GlaxoSmithKline